Abstract
Introduction The I-KID study aims to determine the clinical efficacy, outcomes and safety of a novel non-CE-marked infant haemodialysis machine, the Newcastle Infant Dialysis Ultrafiltration System (NIDUS), compared to currently available therapy in the UK. NIDUS is specifically designed for renal replacement therapy in small babies between 0.8 and 8 kilograms.
Methods and analysis The clinical investigation is taking place in six UK centres. This is a randomised clinical investigation using a cluster stepped-wedge design. The study aims to recruit 95 babies requiring renal replacement therapy in paediatric intensive care units over 20 months.
Registration IRAS ID number: 170481
MHRA Reference: CI/2017/0066
ISRCT Number: 13787486
CPMS ID number: 36558
NHS REC reference: 16/NE/0008
Eudamed number: CIV-GB-18-02-023105
Link to full protocol v6.0: https://fundingawards.nihr.ac.uk/award/14/23/26
What is known about this subject Babies in paediatric intensive care unit (PICU) may develop acute renal failure and require therapeutic support.
Renal replacement options for babies are limited because of their small size and limitations of technology.
Current haemodialysis and filtration systems in use in UK are not recommended or licensed for children under 8kg.
What this study hopes to add Renal replacement methods for infants under 8kg in PICU will be compared.
The efficacy, outcomes and safety of a new infant haemodialysis device will be assessed.
Usability of the new device in normal clinical settings outside of the development centre will be examined.
Competing Interest Statement
The authors have declared no competing interest.
Clinical Trial
ISRCT Number: 13787486
Clinical Protocols
https://fundingawards.nihr.ac.uk/award/14/23/26
Funding Statement
Funding for the study was granted by the National Institute of Health Research UK Efficacy and Mechanism Evaluation Programme (NIHR EME). The Authors and contributors have not received funding from third party.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Favourable ethical opinion was obtained from Tyne and Wear South Research Ethics Committee in 2018 (NHS REC reference: 16/NE/0008). A letter of no objection was obtained from the Medicines and Healthcare products Regulatory Agency (MHRA Reference: CI/2017/0066).
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Data may be made available once the study is complete.
